Venture appraises. It does not assay.
A first check is priced off what is legible before the meeting. Reserve time. An address book with loss-tolerant money in it. None of that says whether the company works.
Venture requires wealth three times before it evaluates anything. We removed the gates and kept the evaluation.
Venture asks for runway, friends-and-family money, and a warm introduction before it looks at the company. We ask for none of them. We build the company beside you at near-zero cost, and you leave knowing how it was built and sold.
A first check is priced off what is legible before the meeting. Reserve time. An address book with loss-tolerant money in it. None of that says whether the company works.
When learning whether a company worked took a year and a million dollars, capital had to be allocated on judgment. The deck, the warm intro, the pattern match were a rational response to an assay nobody could afford to run.
A production product ships in weeks and the infrastructure is credited. Ninety days and about five thousand dollars buy a verdict from named buyers. When the test costs less than the deck, appraisal is the expensive part.
“We are not better guessers. We have stopped guessing.”
Long enough for an enterprise buyer to answer. Short enough for the answer to stay affordable.
A production product in front of one named enterprise buyer, with contract value on the table. Shipped, not demoed.
Studio-run outbound against a defined account list. The founder holds every buyer conversation and every close.
Revenue, slope, early usage, founder-led closes, and objection quality against a single threshold. $100K ARR is the point at which the question stops being subjective.
Four verdicts. The data selects.
A negative verdict ends our operating role. You keep the company, the working assets, and the written methods behind them.
Company-owned repository with full commit history and CI history.
+5 more
CRM with stages, owners, and the full account list scored and loaded.
+5 more
Production code for the shipped wedge, deployed and instrumented.
+5 more
Deploy checklist and the on-call rotation for the first six months.
+5 more
icp-scoring.csv — account scoring with weighted disqualifiers.
+7 more
A prediction is only right or wrong. A verdict has four settings, and we publish all of them.
Revenue and slope enough to underwrite a pre-seed on a $4–6M post-money SAFE. We open the introductions. Seed comes later, off a bigger base.
Real revenue, but short of the $300K–$500K ARR a seed fund will lead. Compound another quarter and reopen introductions, or run it for cash flow.
The proposition holds; the market or the metric is not ready. Low-cost hold with a set re-evaluation date.
The wedge did not land. The company, the code, and every customer stay yours. So does the stack and the method, which is what makes attempt two cheaper. No clawback.
“A kill is a completed experiment. The expensive mistake is keeping the company alive to protect the original bet.”
The method requires the discipline of shipping and closing paying customers. It cannot be run from a term sheet, and it cannot be taught by anyone who has not done it.
One company built as a founder and sold, two more sold as a VP and CMO. Regulated healthcare, where a single enterprise sale takes a year and every buyer conversation is earned.
Several years sourcing early-stage healthcare software into venture pipelines. Dozens of companies judged on the deck, because no evidence existed yet to judge them on.
Three prior exits across regulated healthcare. One built as founder, two through senior-operator roles (VP and CMO). All acquired. Full record →
Additional operating partners announced on joining.
The studio is compensated on a positive commercial outcome. A negative verdict returns ninety days. Equity prices what we supply, so founders who bring buyer access pay less.
You know the buyers. You cannot build.
You can build. You do not know the buyers.
You are one half. We find the other.
Cohort 01 is the first. Every company lands on the record at Day 90 with its verdict, and nothing is announced before a real product sits in front of a real buyer.
“If we only publish wins, the record is marketing. If we publish the kills, it is evidence.”
Jack Gierlich
Managing Partner, Cupel Studio
Two Cohort 01 seats are held, two are open. A company appears on the record once a paying customer is live, alongside the metrics behind its verdict.
The full record →Venture prices a first check off things it can read before evaluating the company at all. We price it off evidence produced inside ninety days: named buyers, a paying contract, a usage curve.
15–25% common, minority, capped at 25%. Access pathway 15% on the 90, 20% on the 180. Technical and Match pathways 20% on the 90, 25% on the 180. Bringing an existing product with real usage reduces the figure by up to three points. Documented before Day 1.
None. Build stack, credits, sales team, and operators are compensated in studio equity. The founder contributes product and time.
The verdict determines the path. GROW if revenue is real but not venture-shaped. PARK if the signal is early. KILL if the wedge did not land, in which case the founder retains the company in full.
The founder. Board majority and CEO seat retained, domain in the company's name. The studio holds a minority preferred stake via the build-value SAFE and an observer seat.
The studio prepares the evidence package and opens the introductions. $100K ARR supports a pre-seed, typically $500K–$1.5M on a $4–6M cap. Seed is a separate event six to twelve months later, off a $300K–$500K ARR base. The founder runs both and closes both.
A short application. An operator replies within seven days.
Apply →